Medivisor Inc. CEO Dino Luzzi Discusses Pharmaceutical Licensing Agreement and Corporate Strategy With CEORoadshow.com in Online Audio Interview

Share Article

Medivisor Inc. (OTC :MVSR) today announced that the Company is presently featured in an online audio interview at http://www.CEORoadshow.com. Mr. Dino Luzzi, CEO of Medivisor, discusses the company's recent announcement of a licensing agreement for the ground breaking chemotherapy drug Mucotrol™ with Cura Pharamaceuticals, and outlines the company's short term growth strategy. The exclusive interview may be viewed and heard by clicking on the following link: http://www.ceoroadshow.com/viewer.asp?VideoID=8

Palm Beach, FL -- Medivisor Inc. (OTC :MVSR) today announced that the Company is presently featured in an online audio interview at http://www.CEORoadshow.com. Mr. Dino Luzzi, CEO of Medivisor, discusses the company's recent announcement of a licensing agreement for the ground breaking chemotherapy drug Mucotrol™ with Cura Pharamaceuticals, and outlines the company's short term growth strategy. The exclusive interview may be viewed and heard by clicking on the following link: http://www.ceoroadshow.com/viewer.asp?VideoID=8

About Medivisor Inc.
Medivisor (OTC:MVSR) is a medical communications company dedicated to providing concise and timely medical information to healthcare industry professionals. Medivisor exclusively serves the bioscience and pharmaceutical markets, offering specialized medical marketing consulting, graphic design, web site marketing strategy, event management, public relations and market research. From pre-product development through product launch and commercialization, Medivisor offers worldwide experience in delivering effective and successful integrated marketing and creative communications campaigns for the mutual benefit of both pharmaceutical vendors as well as the practitioners. The Company recently announced that it has signed a sales and marketing agreement with Cura Pharmaceuticals, Inc. for the marketing of Mucotrol™ within the United States and additional territories. The groundbreaking drug Mucotrol™ is an oral gel wafer that received 510-K approval from the Food and Drug Administration in late November 2004, as a treatment for mouth sores related to chemotherapy. Under the terms of the agreement, Cura Pharmaceutical will supply and distribute Mucotrol™ with Medivisor with the parties agreeing to share 50%/50% in the Net Profits derived from the sales and marketing of the drug in joint territories.

About CEORoadshow.com
http://www.CEORoadshow.com presents detailed interviews with CEOs, company CFOs and analysts, which provides publicly traded companies with production services and distribution of their corporate messages in streaming video/audio format. Your corporate message is delivered firsthand to all major newswires, institutional and private investors, venture capitalists and buy and sell analysts, all at the click of a mouse. Using our state of the art webcasting services, CEORoadshow.com can feature and host CEO interviews, business updates, earning conference calls, analyst presentations, product launches and other special announcements directly to your audience's desktop, at minimal cost compared to video or telephone conferencing. CEORoadshow.com will provide public companies with the means and ability to reach far into the investment community with a direct message to shareholders and potential investors, through our streaming media technology, active databases of institutional and individual investors, analysts, brokerage firms and large affiliate network while providing the most impact for the communications dollar.

Safe Harbor Statement
Statements contained herein, other than historical data, may constitute forward-looking statements. When used in this document, the words "estimate," "project," "intends," "expects," "believes" and similar expressions are intended to identify forward-looking statements regarding events and financial trends, which may affect the Company's future operating results and financial position. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. A complete disclosure of all fees paid to CeoRoadshow.com is available on the Company's disclaimer page as required by Section 17B of the SEC. The Private Securities Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this press release (as well as information included in written statements to be made) contain statements that are forward-looking, such as those relating to consummation of the transaction, anticipated future revenue of the Company's and success of current public offerings. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future and, accordingly, such results may differ materially from those expressed in any forward-looking statements.

Contact:

Medivisor Inc.
631.549.7000
Investor Relations
B. Michael Friedman
212.918.4567

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Michael Friedman
Visit website